国产培美曲塞二钠单药一线治疗老年晚期肺腺癌的近期疗效观察

Clinical efficiency of single-agent domestic pemetrexed disodium used in the first-line for the treatment of elderly patients with advanced lung adenocarcinoma

目的:观察国产培美曲塞二钠一线治疗老年晚期肺腺癌的疗效和不良反应。方法:44例老年晚期肺腺癌患者,其中34例应用国产培美曲塞二钠,10例应用进口培美曲塞二钠,培美曲塞二钠500mg·m-2化疗,2周期后观察疗效和不良反应。结果:44例患者中无完全缓解病例,15例部分缓解,16例稳定,13例进展,总缓解率为34.1%(15/44),疾病控制率为70.4%(31/44),不良反应发生率低,主要为Ⅰ～Ⅱ度骨髓抑制,国产培美曲塞二钠和进口培美曲塞二钠在疗效和不良反应上均无明显差异。结论:国产培美曲塞二钠一线治疗老年晚期肺腺癌有确切疗效,不良反应少。

OBJECTIVE To evaluate the efficacy and safety of domestic pemetrexed disodium home made in the treatment of elderly patients with advanced lung adenocarcinom. METHODS 44 advanced lung adenocarcinoma patients received pemetrexed 500 mg.m 2 for 2cycles. 34 patients received domestic pemetrexed disodium and 10 patients received pemetrexed disodiurn imported. The efficacy and side effects were observed after two therapeutic cycles. RESULTS Among 44 patients, no one got complete response, 15 patients got partial response, I6 patients were stable, and 13 patients without effect. The total response rate was 15/44（34. 1%）, disease control rate was 31/44（70.4%0）. The main toxicity was Grade 1 and 2 hematological toxicities. And there was no significant difference between domestic pemetrexed disodium or imported in the total response rate and disease control rate. CONCLUSION Single-agent domestic pemetrexed disodium is effective and safe in the first-line treat- ment of elder patients with advanced lung adenocarcinoma.